Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
There was no observation related to data integrity reported
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Subscribe To Our Newsletter & Stay Updated
